A fundamental understanding of the molecular mechanism governing osteoblast differentiation is essential for developing novel bone anabolic therapeutics. Physiological Notch signaling has emerged as a critical suppressive mechanism for osteoblast differentiation to ensure a proper pool of mesenchymal progenitors necessary for long-term bone homeostasis. Hyperactivation of NOTCH2 has recently been discover to cause Hajdu-Cheney syndrome (HCS) characterized by childhood osteoporosis, acroosteolysis and wormian bones. Where or not osteoblast or osteoclast defects are the primary cause for the disease has not been established. Moreover, an effective treatment for the disease is currently lacking. Elucidating the cellular basis for the disease and the relationship between NOTCH and other regulators of bone physiology will provide the basis for a rational design of therapeutics. I the current proposal, we test the hypothesis that suppression of osteoblast differentiation by hyperactive NOTCH2 is primarily responsible for HCS, and that stimulation of the bone anabolic WNT pathway may alleviate the bone defects associated with the disease. We further investigate the biochemical basis for the functional antagonism between NOTCH and WNT signaling. Overall, successful completion of this project is expected to provide novel mechanistic insights about the pathogenesis of HCS, and may open new avenues for effective treatments of the disease.
Hajdu-Cheney Syndrome is a rare autosomal dominant disease with early childhood onset. The disease is characterized by general osteoporosis, acroosteolysis and wormian bones. Recent discoveries have revealed that NOTCH2 hyperactivation mutations are responsible for the disease. This proposal is designed to understand the cellular and molecular mechanisms underlying the disease-causing effect of NOTCH2. Research results from this study may open new avenues for effective treatments of the disease.
|Sun, Weiwei; Shi, Yu; Lee, Wen-Chih et al. (2016) Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse. Bone 85:1-8|
|Karner, Courtney M; Esen, Emel; Chen, Jiakun et al. (2016) Wnt Protein Signaling Reduces Nuclear Acetyl-CoA Levels to Suppress Gene Expression during Osteoblast Differentiation. J Biol Chem 291:13028-39|
|Lim, Joohyun; Shi, Yu; Karner, Courtney M et al. (2016) Dual function of Bmpr1a signaling in restricting preosteoblast proliferation and stimulating osteoblast activity in mouse. Development 143:339-47|
|Luo, Xianmin; Fu, Yujie; Loza, Andrew J et al. (2016) Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep 14:82-92|
|Karuppaiah, Kannan; Yu, Kai; Lim, Joohyun et al. (2016) FGF signaling in the osteoprogenitor lineage non-autonomously regulates postnatal chondrocyte proliferation and skeletal growth. Development 143:1811-22|
|Wang, Jirong R; Wang, Chaojun J; Xu, Chengyun Y et al. (2016) Signaling Cascades Governing Cdc42-Mediated Chondrogenic Differentiation and Mensenchymal Condensation. Genetics 202:1055-69|
|Chen, Jianquan; Long, Fanxin (2015) mTORC1 Signaling Promotes Osteoblast Differentiation from Preosteoblasts. PLoS One 10:e0130627|
|Lim, Joohyun; Tu, Xiaolin; Choi, Kyunghee et al. (2015) BMP-Smad4 signaling is required for precartilaginous mesenchymal condensation independent of Sox9 in the mouse. Dev Biol 400:132-8|
|Chen, Jianquan; Holguin, Nilsson; Shi, Yu et al. (2015) mTORC2 signaling promotes skeletal growth and bone formation in mice. J Bone Miner Res 30:369-78|
|Esen, Emel; Lee, Seung-Yon; Wice, Burton M et al. (2015) PTH Promotes Bone Anabolism by Stimulating Aerobic Glycolysis via IGF Signaling. J Bone Miner Res 30:1959-68|
Showing the most recent 10 out of 22 publications